表观遗传学
EZH2型
下调和上调
乙酰化
染色质免疫沉淀
癌症研究
组蛋白
小RNA
神经母细胞瘤
细胞生物学
染色质
化学
表观遗传疗法
生物
组蛋白甲基转移酶
PRC2
分子生物学
细胞周期
调节器
小发夹RNA
细胞凋亡
体细胞
泛素
细胞周期检查点
组蛋白H3
转录调控
作者
Mrunalini Boddu,Atul Dev,Surajit Karmakar
出处
期刊:Small
[Wiley]
日期:2026-03-10
卷期号:22 (25): e12024-e12024
被引量:1
标识
DOI:10.1002/smll.202512024
摘要
Neuroblastoma (NB) is a highly malignant pediatric extracranial tumor with genetic and epigenetic factors influencing its pathogenesis. Key genetic contributors include germline mutations in ALK and PHOX2B, as well as somatic amplification of MYCN. The epigenetic regulator EZH2, a histone methyltransferase of the PRC2 complex, is overexpressed in NB and linked to poor prognosis in advanced cases. Targeting EZH2 offers a promising therapeutic approach due to its role in tumor proliferation, survival, and maintenance of undifferentiated states. This study explores the use of acetylated human serum albumin nanoparticles (HSANPs) loaded with 4O4HPR for epigenetic therapy in NB, tested in vitro and in vivo using nude mice xenograft models. The nanoparticles enter cells via clathrin-mediated endocytosis and induce G2-M cell cycle arrest, mitochondrial depolarization, and the production of reactive oxygen species, which activate Caspase 3 and trigger apoptosis. Mechanistic studies show increased p53 acetylation, stabilizing p53 and inhibiting EZH2's epigenetic silencing. Chromatin Immunoprecipitation reveals the disruption of EZH2 binding to the E-Cadherin promoter, which suppresses cell migration and EMT-like transition. Western blotting confirms upregulation of epithelial and downregulation of mesenchymal markers, with inhibited wound closure in SH-SY5Y cells. This nanotherapy disrupts EZH2-E-Cadherin interaction, offering novel translational potential for NB treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI